Krka (KRK) komunikat - Decision of the Supreme Court of Norway relating to esomeprazole

POLISH FINANCIAL SUPERVISION AUTHORITY
		UNI - EN REPORT No		23	/	2014
Date of issue:	2014-05-13
Short name of the issuer
KRKA
Subject
Decision of the Supreme Court of Norway relating to esomeprazole
Official market - legal basis
Art. 56 ust. 1 pkt 1 Ustawy o ofercie - informacje poufne
Unofficial market - legal basis
Contents of the report:
Krka, d. d., Novo mesto (hereafter Krka) would like to inform the interested public that the Supreme Court in Norway in the proceedings for alleged infringement of the patent NO 307 378, which protects the product esomeprazole with a high optical purity, refused Krka’s request for leave to appeal. By this decision the dispute regarding esomeprazole in Norway is closed. Krka published the announcements considering esomeprazole litigation in Norway on 15 December 2010, 23 June 2011, 23 April 2012 and 5 February 2014.
Annexes
File			Description

KRKA, TOVARNA ZDRAVIL D.D.

(fullname of the issuer)

KRKA

Farmaceutyczny (far)

(short name of the issuer)

(sector according to clasification
of the WSE in Warsow)

8501

Nove Mesto

(post code)

(city)

Smarjeska

(street)

(number)

+386 7 331 21 11

+386 7 332 15 37

(phone number)

(fax)

(e-mail)

(web site)

SI82646716

(NIP)

(REGON)

SIGNATURE OF PERSONS REPRESENTING THE COMPANY
Date	Name	Position / Function	Signature
2014-05-13	Jože Colarič	President of the Management Board

Konta:	Konta osobiste Konta młodzieżowe Konta firmowe Konta walutowe
Kredyty:	Kredyty gotówkowe Kredyty mieszkaniowe Kredyty z dopłatą Kredyty dla firm

Krka
Decision of the Supreme Court of Norway relating to esomeprazole